Research Solutions (RSSS) reported QQ2 2025 results featuring meaningful ARR expansion and a strong rate of Platform deployments, underscoring the company’s progress in monetizing its AI-enabled research workflow platforms. Total revenue rose 15.5% year over year to $11.9 million, with Platform revenue up 47% to $4.6 million and a 39% platform contribution to total revenue. ARR reached $19.1 million, up 23% year over year, driven by a mix shift toward higher-margin Platform deployments and continued Scite/Article Galaxy cross-sell activity. Despite topline progress, GAAP net income declined to a net loss of $1.98 million, and EBITDA was negative at $(1.66) million on a reported basis. Adjusted EBITDA was $0.96 million for the quarter, with trailing-twelve-month EBITDA of approximately $4.6 million, signaling improving cash-generation characteristics even as profitability remains a near-term challenge due to ongoing growth investments and a $2.4 million earn-out provision associated with Scite. Management attributed the ARR strength to a combination of new logo acquisition, a restructured sales organization (corporate vs. academic), and a rebound in academic/B2B activity post-election season. The company signaled continued investments in growth (Sales & Marketing, technology, and product development), with the expectation that Q3-Q4 will be stronger on profitability as growth investments normalize. Management also emphasized a strategic AI focus: vertical, workflow-integrated AI leveraging proprietary content access and rights, capable of plugging into multiple LLMs to improve research outcomes. Near-term guidance remains qualitative, with expectations for sequentially stronger bookings in Q4 and into FY2026 Q1, a normalization of CAC/CAC-to-LTV over time, and continued expansion of both B2B and B2C platforms. Investors should monitor ARR progression, churn and upsell dynamics, platform mix impact on margins, and the evolution of AI-enabled product updates and analytics capabilities.